Press Room

Press Clipping / Feb 08, 2018

Hovione Researcher on month-long study visit to ISAB Labs

LAB BLOG: Inhalation Sciences, February 8, 2018

Hovione Researcher on month-long study visit to ISAB Labs | Hovione

Hovione doctoral researcher Beatriz Noriega returns to ISAB’s labs in Stockholm for her ongoing research into preclinical in vitro dissolution testing. She talks to Lab Blog about why she believes dissolution testing is critical, and how she’s hoping to prove it.

 

Hovione Ph.D. researcher Beatriz Noriega has been working for two years so far on her doctoral thesis, authoring four well-received posters and with two accepted for the next Respiratory Drug Delivery (RDD) Conference in April 2018. This is Beatriz’s second research visit to ISAB’s labs to use the in vitro simulation tool DissolvIt, as part of her work in the Particle Design and Inhalation Development department of Hovione’s R&D Drug Product Development. Her mission? “No matter how similar formulations may seem, until you analyze dissolution you never really know,” says Beatriz. She took time out from her research to talk to our ISAB Lab Blog.

 

 

Read the entire interview at Inhalation.se

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025